TDM useful for some agents in IBD but not TNF-inhibitors

Therapeutic drug monitoring may have a role in treatment decisions in IBD for biologics such as ustekinumab and vedolizumab but not for anti-TNF agents such as adalimumab, findings presented at UEG Week 2020 suggest. Interim results from STARDUST, a treat-to-target (T2T) trial of ustekinumab in 500 patients with moderate to severe Crohns disease have provided ...

Already a member?

Login to keep reading.

© 2021 the limbic